ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...

The PDT business posted 9% growth in 2024. Takeda’s broad immunoglobulin ... The Zacks Consensus Estimate for ADMA’s 2025 sales implies a year-over-year increase of 18.61%, and that ...

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near ...

The U.S. Intravenous Immunoglobulin Market plays a crucial role in treating immunodeficiency diseases and various autoimmune disorders, reflecting a steady evolution influenced by advanced therapies ...

In Q1 2025, Globant’s revenue in the Middle East & APAC region saw an 84.4% year-over-year increase. According to Gartner, IT spending in the MENA region is projected to grow by 7.4% to reach ...

TSM posted 39.6% YoY growth in May, gained share over Samsung, and leads in 2nm yields, all while trading under 20x FY26 EPS.

A high-level overview of Takeda Pharmaceutical Company Limited (TAK) stock. View (TAK) real-time stock price, chart, news, analysis, analyst reviews and more.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to ...

Takeda Investor Conference Call and Webcast Details Takeda will host an investor call regarding this update on Sunday, June 1, 6-6:45 pm CDT/ 7-7:45 pm EDT / Monday, June 2, 08:00-08:45 (JST).

Foxconn reported consolidated revenue of NT$615.745 billion (US$20.55 billion) for May 2025, marking a 3.99% decline compared to April. However, when measured in US dollars, the company said ...